AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12745095 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 100
Study 10855739 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8-16 mg once daily
Number of subjects: 4964
Study 10855739 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 4964
Study 9357355 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step intervention (physician letter and peer counseling call)
Number of subjects: 460
Study 9357355 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 460
Study 8403634 — intervention group
Group type: EXPERIMENTAL
Intervention: Septopal beads
Number of subjects: 35
Study 8403634 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous bone grafts
Number of subjects: 35
Study 8403634 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic antibiotics and/or gentamicin (Septopal) antibiotic beads
Number of subjects: 35
Study 3941533 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed continuing education program on hypertension
Number of subjects: 0
Study 3941533 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mailed education)
Number of subjects: 0
Study 31428854 — intervention group
Group type: EXPERIMENTAL
Intervention: G+1.50 (additional 1500 mL of water)
Number of subjects: 115
Study 31428854 — intervention group
Group type: EXPERIMENTAL
Intervention: G+2.25 (additional 2250 mL of water)
Number of subjects: 115
Study 31428854 — intervention group
Group type: COMPARATOR
Intervention: CON (no additional water)
Number of subjects: 115
Study 31428854 — intervention group
Group type: EXPERIMENTAL
Intervention: G+0.50 (additional 500 mL of water)
Number of subjects: 115
Study 31428854 — intervention group
Group type: EXPERIMENTAL
Intervention: G+1.00 (additional 1000 mL of water)
Number of subjects: 115
Study 31428854 — intervention group
Group type: EXPERIMENTAL
Intervention: G+1.50 and G+2.25
Number of subjects: 115
Study 30191972 — intervention group
Group type: EXPERIMENTAL
Intervention: Avatrombopag (20 mg/day)
Number of subjects: 49
Study 30191972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 26811524 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin (GO)
Number of subjects: 237
Study 26811524 — intervention group
Group type: COMPARATOR
Intervention: Best Supportive Care (BSC)
Number of subjects: 237
Study 24908236 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular aerobic exercise (30 min, 3 times a week for 3 months)
Number of subjects: 15
Study 24908236 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy lean women, no intervention)
Number of subjects: 15
Study 24205150 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse home visits during pregnancy and until the child's second birthday
Number of subjects: 460
Study 24205150 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 460
Study 21165734 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion
Number of subjects: 60
Study 21165734 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl infusion
Number of subjects: 60
Study 18312772 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/day)
Number of subjects: 125
Study 18312772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 17000891 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab (n=15)
Number of subjects: 29
Study 17000891 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide (n=14)
Number of subjects: 29
Study 17000891 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH; 70 U/kg bolus)
Number of subjects: 29
Study 14531242 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized albuterol 2.5 mg
Number of subjects: 20
Study 14531242 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized levalbuterol 1.25 mg
Number of subjects: 20
Study 10763958 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg p.o., b.i.d. for 1 month)
Number of subjects: 16
Study 10763958 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 1 month)
Number of subjects: 16
Study 8881614 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% hyperbaric bupivacaine (3.2‐3.6 ml, 8‐9 mg)
Number of subjects: 60
Study 8881614 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% hyperbaric bupivacaine (3.6‐4.0 ml, 9‐10 mg)
Number of subjects: 60
Study 8881614 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% hyperbaric bupivacaine (4.0‐4.4 ml, 10‐11 mg)
Number of subjects: 60
Study 8881614 — intervention group
Group type: COMPARATOR
Intervention: Control group (3.2‐3.6 ml, 8‐9 mg)
Number of subjects: 60
Study 1357550 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol (50 micrograms, twice daily)
Number of subjects: 24
Study 1357550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 3082733 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary parenteral nutrition (200 mg nitrogen per kg per day via central catheter)
Number of subjects: 40
Study 3082733 — intervention group
Group type: COMPARATOR
Intervention: Oral diet (40 kcal per kg per day)
Number of subjects: 40
Study 3082733 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary parenteral nutrition
Number of subjects: 40
Study 29135458 — intervention group
Group type: EXPERIMENTAL
Intervention: HVLA manipulation (MT group)
Number of subjects: 25
Study 29135458 — intervention group
Group type: EXPERIMENTAL
Intervention: CCF exercise protocol (CCF group)
Number of subjects: 25
Study 27153085 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial meal replacement program with app support
Number of subjects: 146
Study 25436614 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine (ASAQ)
Number of subjects: 413
Study 25436614 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 413
Study 25436614 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine (ASAQ) and Artemether-lumefantrine (AL)
Number of subjects: 413
Study 22584529 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver lipidocolloid dressing
Number of subjects: 0
Study 22584529 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 20446755 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukotriene receptor antagonists (LTRAs)
Number of subjects: 361
Study 20446755 — intervention group
Group type: COMPARATOR
Intervention: Long-acting beta2 agonists
Number of subjects: 361
Study 18593773 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone replacement therapy in group A (22 patients)
Number of subjects: 35
Study 18593773 — intervention group
Group type: COMPARATOR
Intervention: Control group (35 healthy men)
Number of subjects: 35
Study 18593773 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard replacement therapy without GH in group B (13 patients)
Number of subjects: 35
Study 18830566 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg IV on admission, followed by 20 mg orally for 7 days
Number of subjects: 237
Study 18830566 — intervention group
Group type: COMPARATOR
Intervention: Control group (no gastric acid inhibitor)
Number of subjects: 237
Study 18830566 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole group
Number of subjects: 237
Study 18830566 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 237
Study 15866357 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (AA)
Number of subjects: 18
Study 15866357 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF)
Number of subjects: 18
Study 15866357 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation
Number of subjects: 18
Study 15866357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 11177112 — intervention group
Group type: EXPERIMENTAL
Intervention: Biperiden hydrochloride
Number of subjects: 12
Study 11177112 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine hydrochloride
Number of subjects: 12
Study 11177112 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 12
Study 11177112 — intervention group
Group type: COMPARATOR
Intervention: Air (as placebo)
Number of subjects: 12
Study 9757147 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg ketoconazole twice a day plus 1.0 mg alprazolam
Number of subjects: 5
Study 9757147 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg ketoconazole twice a day plus 0.25 mg triazolam
Number of subjects: 5
Study 9757147 — intervention group
Group type: COMPARATOR
Intervention: ketoconazole placebo plus 1.0 mg alprazolam
Number of subjects: 5
Study 9757147 — intervention group
Group type: COMPARATOR
Intervention: ketoconazole placebo plus 0.25 mg triazolam
Number of subjects: 5
Study 7923801 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxene Sodium (550 mg) 30 minutes before surgery
Number of subjects: 63
Study 7923801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 7923801 — intervention group
Group type: COMPARATOR
Intervention: No drug
Number of subjects: 63
Study 3410590 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyclothiazide (M)
Number of subjects: 8
Study 3410590 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Methyclothiazide with Triamterene (25, 50, 75 mg)
Number of subjects: 8
Study 3410590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31927021 — intervention group
Group type: EXPERIMENTAL
Intervention: Video conveying university commitment to cultural diversity and inclusion (n = 45)
Number of subjects: 84
Study 31927021 — intervention group
Group type: COMPARATOR
Intervention: Control video depicting a campus tour (n = 39)
Number of subjects: 84
Study 31466930 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive Self‐ligating brackets: Smart Clip (3M Unitek)
Number of subjects: 42
Study 31466930 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Self‐ligating brackets: Empower AO (American Orthodontics)
Number of subjects: 42
Study 31466930 — intervention group
Group type: COMPARATOR
Intervention: Conventional brackets (3M Unitek)
Number of subjects: 42
Study 28985308 — intervention group
Group type: EXPERIMENTAL
Intervention: STOP Diabetes education programme (multi-component lifestyle behaviour change intervention)
Number of subjects: 0
Study 26182440 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3 + CAF
Number of subjects: 10
Study 26182440 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3
Number of subjects: 10
Study 26182440 — intervention group
Group type: EXPERIMENTAL
Intervention: All experimental conditions
Number of subjects: 10
Study 26182440 — intervention group
Group type: COMPARATOR
Intervention: Rating of perceived exertion
Number of subjects: 10
Study 27129013 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3839 (1-300 mg single oral doses)
Number of subjects: 54
Study 22390677 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacopa monnieri (CDRI08 300 mg/day)
Number of subjects: 465
Study 22390677 — intervention group
Group type: EXPERIMENTAL
Intervention: Pycnogenol (150 mg/day)
Number of subjects: 465
Study 22390677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 465
Study 19351782 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotrol nasal spray (actual and expected doses varied)
Number of subjects: 48
Study 19351782 — intervention group
Group type: COMPARATOR
Intervention: No-spray control
Number of subjects: 48
Study 17314698 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with eight graded intakes of phenylalanine without tyrosine
Number of subjects: 5
Study 16278986 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil (125 mg capsules, twice a day for 10 days)
Number of subjects: 82
Study 16278986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 12133084 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diazepam 10 mg (n=56)
Number of subjects: 112
Study 12133084 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=56)
Number of subjects: 112
Study 12133084 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 112
Study 10101984 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-hour physician workshop followed by information provided before each visit on patient expectations, illness worry, and DSM-IV disorders.
Number of subjects: 500
Study 7771834 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin E for 4 weeks, vitamin C and allopurinol 2 days before and 1 day after coronary artery bypass grafting (Group 1)
Number of subjects: 81
Study 7771834 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E given only 2 days before the operation, vitamin C and allopurinol (Group 3)
Number of subjects: 81
Study 7771834 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 2)
Number of subjects: 81
Study 7771834 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 4)
Number of subjects: 81
Study 2335704 — intervention group
Group type: EXPERIMENTAL
Intervention: nonpreserved drops
Number of subjects: 45
Study 2335704 — intervention group
Group type: COMPARATOR
Intervention: 10 different drops
Number of subjects: 45
Study 387216 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent combination therapy
Number of subjects: 121
Study 387216 — intervention group
Group type: COMPARATOR
Intervention: Single-drug chemotherapy administered sequentially
Number of subjects: 121
Study 29790122 — intervention group
Group type: EXPERIMENTAL
Intervention: Modulating circle providing information about onset, offset, and acoustic amplitude envelope of speech
Number of subjects: 0
Study 29790122 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 28557552 — intervention group
Group type: EXPERIMENTAL
Intervention: Family discord present
Number of subjects: 610
Study 27333830 — intervention group
Group type: EXPERIMENTAL
Intervention: BNG-1
Number of subjects: 42
Study 27333830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 27333830 — intervention group
Group type: EXPERIMENTAL
Intervention: BNG-1 and Placebo
Number of subjects: 42
Study 23374147 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Intravenous Anesthesia with Target-Controlled Infusion (TIVA-TCI)
Number of subjects: 28
Study 23374147 — intervention group
Group type: COMPARATOR
Intervention: Balanced Inhalation Anesthesia (BAL)
Number of subjects: 28
Study 19939864 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil plus gabapentin
Number of subjects: 0
Study 19939864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19095858 — intervention group
Group type: EXPERIMENTAL
Intervention: CSE (intrathecal bupivacaine 2.5 mg with fentanyl 25 microg)
Number of subjects: 100
Study 19095858 — intervention group
Group type: COMPARATOR
Intervention: EPID (epidural bupivacaine 2.5 mg/mL, 3 mL, followed by bupivacaine 1.25 mg/mL, 10 mL with fentanyl 50 microg)
Number of subjects: 100
Study 19095858 — intervention group
Group type: EXPERIMENTAL
Intervention: CSE
Number of subjects: 100
Study 19095858 — intervention group
Group type: COMPARATOR
Intervention: EPID
Number of subjects: 100
Study 18075414 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone scintigraphy (early static images)
Number of subjects: 100
Study 15154290 — intervention group
Group type: EXPERIMENTAL
Intervention: Active acupuncture
Number of subjects: 40
Study 15154290 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 40
Study 11134829 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (20 mg/kg rectally)
Number of subjects: 61
Study 11134829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 11134829 — intervention group
Group type: COMPARATOR
Intervention: Reference group (n=66) with uncomplicated pregnancy and delivery in vertex position without vacuum extraction
Number of subjects: 61
Study 9725547 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg cerivastatin daily for 7 days
Number of subjects: 48
Study 9725547 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 48
Study 7994829 — intervention group
Group type: EXPERIMENTAL
Intervention: Encainide or Flecainide (active therapy)
Number of subjects: 1991
Study 7994829 — intervention group
Group type: EXPERIMENTAL
Intervention: Moricizine (active therapy)
Number of subjects: 1991
Study 7994829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1991
Study 2845305 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-shot CMV hyperimmunoglobulin
Number of subjects: 120
Study 2845305 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon alpha 2
Number of subjects: 120
Study 2845305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 30906977 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation intervention (n = 15)
Number of subjects: 30
Study 30906977 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 15)
Number of subjects: 30
Study 27377678 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish (TMAO source)
Number of subjects: 40
Study 27377678 — intervention group
Group type: EXPERIMENTAL
Intervention: Eggs (choline source)
Number of subjects: 40
Study 27377678 — intervention group
Group type: EXPERIMENTAL
Intervention: Beef (carnitine source)
Number of subjects: 40
Study 27377678 — intervention group
Group type: COMPARATOR
Intervention: Fruit (control)
Number of subjects: 40
Study 25772766 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVIGATE program
Number of subjects: 0
Study 25772766 — intervention group
Group type: COMPARATOR
Intervention: Usual community care
Number of subjects: 0
Study 23604013 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation of radiation exposure/health risk information
Number of subjects: 112
Study 23604013 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation of Medicare reimbursement information
Number of subjects: 112
Study 23604013 — intervention group
Group type: COMPARATOR
Intervention: Initial imaging choice without guideline recommendations
Number of subjects: 112
Study 21307142 — intervention group
Group type: COMPARATOR
Intervention: recFSH started on cycle day 2 (CD2)
Number of subjects: 76
Study 21307142 — intervention group
Group type: EXPERIMENTAL
Intervention: recFSH started on cycle day 5 (CD5)
Number of subjects: 76
Study 21307142 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CD2 and CD5)
Number of subjects: 76
Study 19812460 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive, computer‐based cognitive training (100 min/d, 5 d/wk for 6 weeks)
Number of subjects: 47
Study 19812460 — intervention group
Group type: COMPARATOR
Intervention: Passive computer activities (reading, listening, visuospatial game) for similar amounts of time
Number of subjects: 47
Study 16903198 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide paste (Group 1)
Number of subjects: 90
Study 16903198 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate (MTA) (Group 2)
Number of subjects: 90
Study 14703540 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised controlled trials with adequate allocation concealment
Number of subjects: 56
Study 14703540 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised controlled trials with intention to treat analysis
Number of subjects: 56
Study 14703540 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised controlled trials with sample size calculation
Number of subjects: 56
Study 14703540 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised controlled trials with clearly defined endpoints and prespecified alpha and beta errors
Number of subjects: 56
Study 14703540 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting of drop outs in randomised controlled trials
Number of subjects: 56
Study 11679144 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based medicine (EBM)
Number of subjects: 0
Study 11679144 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 9855480 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystokinin octapeptide (CCK-8) infusion (4 ng/kg/min)
Number of subjects: 15
Study 9855480 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 15
Study 7925258 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal effort, 80%, 60%, 40%, and 20% (of the maximal) effort in pinching, gripping and stoop lifting for three trials.
Number of subjects: 10
Study 7925258 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived 60% and 80% of maximal voluntary contractions (MVC)
Number of subjects: 10
Study 7925258 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived 20% of maximal voluntary contractions (MVC)
Number of subjects: 10
Study 7925258 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived 40% effort
Number of subjects: 10
Study 7925258 — intervention group
Group type: EXPERIMENTAL
Intervention: Reliability of perception
Number of subjects: 10
Study 2680581 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg terbutaline powder by Bricanyl Turbuhaler
Number of subjects: 22
Study 2680581 — intervention group
Group type: COMPARATOR
Intervention: 5 mg terbutaline by a conventional jet nebulizer (Pari Inhalierboy)
Number of subjects: 22
Study 1092245 — intervention group
Group type: EXPERIMENTAL
Intervention: Ru‐Vert (25 mg pentylenetetrazol, 12.5 mg pheniramine maleate, 50 mg nictonic acid) at a dosage of two tablets t.i.d.
Number of subjects: 17
Study 31866471 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy boost
Number of subjects: 200
Study 31866471 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 200
Study 31669450 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigation (PN)
Number of subjects: 754
Study 31669450 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified directly observed therapy (mDOT)
Number of subjects: 754
Study 29069041 — intervention group
Group type: COMPARATOR
Intervention: fiber-free nutrition formula (FF group)
Number of subjects: 120
Study 29069041 — intervention group
Group type: EXPERIMENTAL
Intervention: fiber-enriched nutrition formula (FE group)
Number of subjects: 120
Study 29069041 — intervention group
Group type: EXPERIMENTAL
Intervention: fiber- and probiotic-enriched nutrition formula (FEP group)
Number of subjects: 120